In an interview with Technology Networks, Professor Henrik Zetterberg discussed recent advancements in dementia diagnostics, emphasizing the critical role of biomarkers in detecting Alzheimer’s disease (AD) at its earliest stages. He discussed Capitainer’s novel technology for quantitative dried blood and plasma sampling, enabling remote and accessible biomarker testing, since the samples are stable in room temperature for up to 6 months. Using this technique, combined with ultra-sensitive proteomics, it’s possible to measure all key blood biomarkers for Alzheimer’s disease. According to Zetterbeg, this innovation promises to democratize AD diagnostics.

Zetterberg also discussed the urgent need for a reliable blood-based algorithm to both diagnose Alzheimer’s and detect amyloid-related imaging abnormalities (ARIA) in patients receiving anti-amyloid therapies. He highlighted the importance of comprehensive biomarker panels for non-Alzheimer’s dementias, including those that address neuroinflammation and cerebrovascular health. Acknowledging the potential impact of these new therapies, Zetterberg emphasized that accessible blood-based biomarkers, particularly through advancements like dried blood plasma sampling, could significantly advance dementia care and research globally.

Professor Zetterbergand his team have used Capitainer®B50 and were one of the first users, pre-launch, of our new device Capitainer®SEP10.

Read the full article here.